This listing of claims will replace all prior versions of claims in the application.

Listing of Claims: Please amend the claims as follows:

We claim:

Claim 1. (Currently Amended) A compound of the formula I



I

~~in which~~ wherein

R^1 is H, A or SO_2A,

A is straight-chain or branched alkyl having from 1 to 10 carbon atoms, alkenyl having from 2 to 10 carbon atoms or alkoxyalkyl having from 2 to 10 carbon atoms, and

D-E is $R^2C=CR^4$ or $R^2R^3C\text{-}CR^4R^5$,

~~in which~~ wherein

R^2, R^3, R^4 and R^5 are ~~selected~~, independently, ~~from~~ A, cycloalkyl having from 3 to 7 carbon atoms, Hal, CH_2Hal, $CH(Hal)_2$, $C(Hal)_3$, NO_2, $(CH_2)_nCN$, $(CH_2)_nN(R^6)_2$, $(CH_2)_nN(R^6)Ar$, $(CH_2)_nN(R^6)Het$, $(CH_2)_nN(Ar)_2$, $(CH_2)_nN(Het)_2$, $(CH_2)_nCOOR^6$, $(CH_2)_nCOOAr$, $(CH_2)_nCOOHet$, $(CH_2)_nCON(R^6)_2$, $(CH_2)_nCON(R^6)Ar$, $(CH_2)_nCON(R^6)Het$, $(CH_2)_nCON(Ar)_2$, $(CH_2)_nCON(Het)_2$, $(CH_2)_nNR^6COR^6$, $(CH_2)_nNR^6CON(R^6)_2$, $(CH_2)_nNR^6SO_2A$, $(CH_2)_nSO_2N(R^6)_2$, $(CH_2)_nSO_2NR^6(CH_2)_mAr$, $(CH_2)_nSO_2NR^6(CH_2)_mHet$, $(CH_2)_nS(O)_wR^6$, $(CH_2)_nS(O)_wAr$, $(CH_2)_nS(O)_wHet$, $(CH_2)_nOOCR^6$, $(CH_2)_nHet$, $(CH_2)_nAr$,

$(CH_2)_nCOR^6$, $(CH_2)_nCO(CH_2)_mAr$, $(CH_2)_nCO(CH_2)_mHet$, $(CH_2)_nCOO(CH_2)_mAr$, $(CH_2)_nCOO(CH_2)_mHet$, $(CH_2)_nOR^6$, $(CH_2)_nO(CH_2)_mAr$, $(CH_2)_nO(CH_2)_mHet$, $(CH_2)_nSR^6$, $(CH_2)_nS(CH_2)_mAr$, $(CH_2)_nS(CH_2)_mHet$, $(CH_2)_nN(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)(CH_2)_mHet$, $(CH_2)_nSO_2N(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)SO_2(CH_2)_mAr$, $(CH_2)_nSO_2N(R^6)(CH_2)_mHet$, $(CH_2)_nN(R^6)SO_2(CH_2)_mHet$, $(CH_2)_nCON(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)CO(CH_2)_mAr$, $(CH_2)_nCON(R^6)(CH_2)_mHet$, $(CH_2)_nN(R^6)CO(CH_2)_mHet$, CH=N-OA, CH_2CH=N-OA, $(CH_2)_nNHOA$, $(CH_2)_nCH$=N-Het, $(CH_2)_nOCOR^6$, $(CH_2)_nOC(O)N(R^6)_2$, $(CH_2)_nOC(O)NR^6(CH_2)_mAr$, $(CH_2)_nOC(O)NR^6(CH_2)_mHet$, $(CH_2)_nNR^6COOR^6$, $(CH_2)_nNR^6COO(CH_2)_mAr$, $(CH_2)_nNR^6COO(CH_2)_mHet$, $(CH_2)_nN(R^6)CH_2CH_2OR^6$, $(CH_2)_nN(R^6)CH_2CH_2OCF_3$, $(CH_2)_nN(R^6)C(R^6)HCOOR^6$, $(CH_2)_nN(R^6)CH_2COHet$, $(CH_2)_nN(R^6)CH_2Het$, $(CH_2)_nN(R^6)CH_2CH_2N(R^6)CH_2COOR^6$, $(CH_2)_nN(R^6)CH_2CH_2N(R^6)_2$, $CH=CHCOOR^6$, $CH=CHCH_2NR^6Het$, $CH=CHCH_2N(R^6)_2$, $CH=CHCH_2OR^6$, $(CH_2)_nN(COOR^6)COOR^6$, $(CH_2)_nN(CONH_2)COOR^6$, $(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^6)COOR^6$, $(CH_2)_nN(CH_2CONH_2)COOR^6$, $(CH_2)_nN(CH_2CONH_2)CONH_2$, $(CH_2)_nCHR^6COR^6$, $(CH_2)_nCHR^6COOR^6$, $(CH_2)_nCHR^6CH_2OR^6$, $(CH_2)_nOCN$ or $(CH_2)_nNCO$,

~~in which~~ wherein

R^6 is ~~selected~~, independently, ~~from~~ H, A or cycloalkyl having from 3 to 7 carbon atoms,

Het is a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic radical which is unsubstituted or mono- or poly-substituted by A, Hal, NO_2, CN, OR^6, $N(R^6)_2$, $COOR^6$, $CON(R^6)_2$, NR^6COR^6, $NR^6CON(R^6)_2$, NR^6SO_2A, COR^6, $SO_2N(R^6)_2$, $S(O)_wA$ and/or $OOCR^6$,

Ar is an aromatic hydrocarbon radical having from 6 to 14 carbon atoms which is unsubstituted or mono- or polysubstituted by A, Hal, NO_2, CN, OR^6, $N(R^6)_2$, $COOR^6$, $CON(R^6)_2$, NR^6COR^6, $NR^6CON(R^6)_2$, NR^6SO_2A, COR^6, $SO_2N(R^6)_2$, $S(O)_wA$ and/or $OOCR^6$,

w is 0, 1, 2 or 3, and

n and m, independently of one another, are 0, 1, 2, 3, 4 or 5;

X^1 is $(CHR^7)_g$ or $(CHR^7)_h$-Q-$(CHR^8)_k$, ~~in which~~ wherein

Q is ~~selected from~~ O, S, N-R^6, $(O\text{-}CHR^7)_g$, $(CHR^7\text{-}O)_g$, $CR^9=CR^{10}$, $(O\text{-}CHR^9CHR^{10})_g$, $(CHR^9CHR^{10}\text{-}O)_g$, C=O, C=S, $C=NR^6$, $CH(OR^6)$, $C(OR^6)(OR^6)$, C(=O)O, OC(=O), OC(=O)O, $C(=O)N(R^6)$, $N(R^6)C(=O)$, $C(=S)N(R^6)$, $N(R^6)C(=S)$, $OC(=O)N(R^6)$, $N(R^6)C(=O)O$, CH=N-O, $CH=N\text{-}NR^6$, $OC(O)NR^6$, $NR^6C(O)O$, S=O, SO_2, SO_2NR^6 ~~and~~ or NR^6SO_2,

g is 1, 2, 3, 4, 5 or 6,

h and k, independently of one another, are 0, 1, 2, 3, 4, 5 or 6,

and

R^7, R^8, R^9, R^{10} and R^{12}, independently of one another, are as defined for R^2 to R^5;

p is 0, 1, 2 or 3,

E is H, A, $(CH_2)_n$Het, $(CH_2)_n$Ar or cycloalkyl having from 3 to 7 carbon atoms,

G is an optionally substituted alkylene radical having from 1 to 4 carbon atoms, where the substituents are selected from the meanings indicated for R^4,

or

E and G, together with the N atom to which they are bonded, are an unsubstituted or substituted 5-, 6- or 7-membered, mono- or bicyclic heterocyclic radical, which may have 1, 2 or 3 further heteroatoms selected from N, O and S,

X^2 is a bond or is selected, independently, from the meanings indicated for X^1,

Z is H or is a saturated, mono- or polyethylenically unsaturated or aromatic carbocyclic radical having from 5 to 10 carbon atoms or a saturated, mono- or polyethylenically unsaturated or aromatic heterocyclic radical having from 4 to 9 carbon atoms, where the carbocyclic or heterocyclic radical may be mono- or polysubstituted, where the substituents are ~~selected~~, independently of one another, ~~from~~ comprise the meanings of R^2 to R^5 other than H, and wherein the heterocyclic radical contains from 1 to 4 heteroatoms which is ~~selected~~, independently of one another, ~~from~~ N, O ~~and~~ or S,

and

Hal is F, Cl, Br or I,

or a pharmaceutically acceptable salt, solvate, stereoisomer or mixture thereof.

Claim 2. (Currently Amended) The compound of the formula I according to Claim 1, ~~in which~~ wherein

A is straight-chain alkyl having from 1 to 4 carbon atoms or branched alkyl having from 3 to 6 carbon atoms, and

D-E is $R^2C=CR^4$ or $R^2R^3C-CR^4R^5$,
in which R^2, R^3 and R^5 are selected, independently, from A and cycloalkyl having from 3 to 7 carbon atoms,
and

R^4 is Hal, CH_2Hal, $CH(Hal)_2$, $C(Hal)_3$, NO_2, $(CH_2)_nCN$, $(CH_2)_nCOOR^6$, $(CH_2)_nCON(R^6)_2$, $(CH_2)_nNR^6COR^6$, $(CH_2)_nNR^6CON(R^6)_2$, $(CH_2)_nNR^6SO_2A$, $(CH_2)_nSO_2N(R^6)_2$, $(CH_2)_nS(O)_wA$, $(CH_2)_nOOCR^6$, $(CH_2)_nCOR^6$, $(CH_2)_nCO(CH_2)_mAr$, $(CH_2)_nCO(CH_2)_mHet$, $(CH_2)_nCOO(CH_2)_mAr$, $(CH_2)_nCOO(CH_2)_mHet$, $(CH_2)_nOR^6$, $(CH_2)_nO(CH_2)_mAr$, $(CH_2)_nO(CH_2)_mHet$, $(CH_2)_nSR^6$, $(CH_2)_nS(CH_2)_mAr$, $(CH_2)_nS(CH_2)_mHet$, $(CH_2)_nN(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)(CH_2)_mHet$, $(CH_2)_nSO_2N(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)SO_2(CH_2)_mAr$, $(CH_2)_nSO_2N(R^6)(CH_2)_mHet$, $(CH_2)_nN(R^6)SO_2(CH_2)_mHet$, $(CH_2)_nCON(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)CO(CH_2)_mAr$, $(CH_2)_nCON(R^6)(CH_2)_mHet$, $(CH_2)_nN(R^6)CO(CH_2)_mHet$, $(CH_2)_nN(R^6)_2$, $(CH_2)_nOCOR^6$, $(CH_2)_nOC(O)N(R^6)_2$, $(CH_2)_nOC(O)NR^6(CH_2)_mAr$, $(CH_2)_nOC(O)NR^6(CH_2)_mHet$, $(CH_2)_nNR^6COOR^6$, $(CH_2)_nNR^6COO(CH_2)_mAr$, $(CH_2)_nNR^6COO(CH_2)_mHet$, $(CH_2)_nN(R^6)CH_2CH_2OR^6$, $(CH_2)_nN(R^6)CH_2CH_2OCF_3$, $(CH_2)_nN(R^6)C(R^6)HCOOR^6$, $(CH_2)_nN(R^6)CH_2COHet$, $(CH_2)_nN(R^6)CH_2Het$, $(CH_2)_nN(R^6)CH_2CH_2N(R^6)CH_2COOR^6$, $(CH_2)_nN(R^6)CH_2CH_2N(R^6)_2$, $CH=CHCOOR^6$, $(CH_2)_nN(COOR^6)COOR^6$, $(CH_2)_nN(CONH_2)COOR^6$, $(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^6)COOR^6$, $(CH_2)_nN(CH_2CONH_2)COOR^6$, $(CH_2)_nN(CH_2CONH_2)CONH_2$, $(CH_2)_nCHR^6COR^6$, $(CH_2)_nCHR^6COOR^6$ or $(CH_2)_nCHR^6CH_2OR^6$,

m is 0, 1, 2, 3, 4 or 5 and

n 0 or 1;

X^1 is $(CHR^7)_g$ or Q-$(CHR^8)_k$, in which

Q is selected from O, S, N-R^6, (O-CHR^7)$_g$, (CHR^7-O)$_g$, CR^9=CR^{10}, (O-CHR^9CHR^{10})$_g$, (CHR^9CHR^{10}-O)$_g$, C=O, C=S, C=NR^6, $C(OR^6)(OR^6)$, C(=O)O, OC(=O), OC(=O)O, C(=O)N(R^6), N(R^6)C(=O), OC(=O)N(R^6), N(R^6)C(=O)O, CH=N-O, CH=N-NR^6, OC(O)NR^6, NR^6C(O)O, S=O, SO_2, SO_2NR^6 and NR^6SO_2,

g is 2, 3 or 4,

k is 1, 2 or 3, and

R^7, R^8, R^9 and R^{10} are selected, independently, from the meanings indicated for R^2 to R^5;

X^2 is a bond or independently is $(CHR^7)_g$ or Q-$(CHR^8)_k$, in which

Q is selected from O, S, N-R^6, (O-CHR^7)$_g$, (CHR^7-O)$_g$, (O-CHR^9CHR^{10})$_g$, (CHR^9CHR^{10}-O)$_g$, C=O, CH(OR^6), C(=O)O, OC(=O), C(=O)N(R^6), N(R^6)C(=O),S=O, SO_2, SO_2NR^6 and NR^6SO_2, where

g in X^2 is ~~preferably~~ 1 or 2 and k in X^2 is ~~preferably~~ 0 or 1, and

R^{12} is selected, independently, from the meanings of R^4 other than H,

or a pharmaceutically acceptable salt, solvate, stereoisomer or mixture thereof.

Claim 3. (Currently Amended) The compound according to Claim 1, ~~selected from compounds~~ of ~~the~~ formula Ia,



Ia

~~in which~~ wherein

R^1, D-E and Z are as defined above, and ~~in which~~ wherein

X^1 is $(CHR^7)_g$ or $(CHR^7)_h$-Q-$(CHR^8)_k$, ~~in which~~ wherein

Q is ~~selected from~~ O, S, N-R^6, (O-$CHR^7)_g$, $(CHR^7$-O$)_g$, CR^9=CR^{10}, (O-$CHR^9CHR^{10})_g$, $(CHR^9CHR^{10}$-O$)_g$, C=O, C=S, C=NR^6, $CH(OR^6)$, $C(OR^6)(OR^6)$, C(=O)O, OC(=O), OC(=O)O, C(=O)N(R^6), N(R^6)C(=O), OC(=O)N(R^6), N(R^6)C(=O)O, CH=N-O, CH=N-NR^6, OC(O)NR^6, NR^6C(O)O, S=O, SO_2, SO_2NR^6 ~~and~~ or NR^6SO_2,

g is 1, 2, 3, 4, 5 or 6,

h and k, independently of one another, are 0, 1, 2, 3, 4, 5 or 6, and

R^6 is selected, independently, from H, A or cycloalkyl having from 3 to 7 carbon atoms,

R^7, R^8, R^9 and R^{10} are selected, independently, from the meanings indicated for R^2 to R^5;

Y is CH, N, COR^{11}, CSR^{11}, an unsubstituted or substituted, spiro-linked carbocyclic radical having from 5 to 7 carbon atoms or an unsubstituted or substituted, spiro-linked, 5-, 6- or 7-membered heterocyclic radical having from 1 to 3 heteroatoms selected from N, S or O,

R^{11} is H, A, $(CH_2)_nHet$, $(CH_2)_nAr$ or cycloalkyl having from 3 to 7 carbon atoms,

X^2 is a bond or O, S, N-R^7, CH_2 or CH_2CH_2,

p, q and r, independently of one another, are 0, 1, 2 or 3

and

Hal is F, Cl, Br or I, and

R^{12} and R^{13}, independently of one another, Hal, CN, NO_2, OR^6, $N(R^6)_2$, NO_2, CN, $COOR^6$, $CON(R^6)_2$, NR^6COR^6, $NR^6CON(R^6)_2$, NR^6SO_2A, COR^6, SO_2NR^6, $S(O)_wA$, $OOCR^6$ and/or C(NH)NOH,

or a pharmaceutically acceptable salt, solvate, stereoisomer or mixture thereof.

Claim 4. (Currently Amended) A compound ~~of the formula~~ which is

a) 6-{3-[4-(4-fluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

b) 6-{3-[4-(2,4-difluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

c) 6-{3-[4-(4-fluorophenoxy)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

d) 4-{3-[4-(4-fluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

e) 4-{3-[4-(2,4-difluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

f) 4-{3-[4-(4-fluorophenoxy)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

g) 5-{3-[4-(4-fluorophenoxy)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

h) 5-{3-[4-(4-fluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

i) 5-{3-[4-(2,4-difluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

j) 5-{3-[4-(4-cyanophenyl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

k) 5-{4-[3-(3-cyano-1H-indol-6-yl)propyl]piperazin-1-yl}benzofuran-2-carboxamide;

l) 5-{3-[4-(2-oxo-2H-chromen-6-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

m) 5-{4-[3-(3-cyano-1H-indol-4-yl)propyl]piperazin-1-yl}-benzofuran-2-carboxamide;

n) 5-{4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl}-benzofuran-2-carboxamide;

o) 5-{3-[4-(1H-indol-4-yl)-piperazin-1-yl]propyl}-1-methanesulfonyl-1H-indole-3-carbonitrile;

p) 5-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-1H-indole-3-carbonitrile;

q) 5-[3-(4-benzo[1,2,5]thiadiazol-4-ylpiperazin-1-yl)propyl]-1H-indole-3-carbonitrile;

r) 3-{1-[3-(3-cyano-1H-indol-5-yl)propyl]piperidin-4-yl}-1H-indole-5-carboxamide;

s) 5-[3-(4-quinolin-8-ylpiperazin-1-yl)propyl]-1H-indole-3-carbonitrile;

t) 5-{3-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

u) 1-methanesulfonyl-5-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-1H-indole-3-carbonitrile;

v) 5-{3-[4-(1H-indol-4-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

w) 5-{3-[4-(1H-indol-3-yl)piperidin-1-yl]propyl}-1H-indole-3-carbonitrile;

x) 5-{3-[4-(5-fluoro-1H-indol-3-yl)piperidin-1-yl]propyl}-1H-indole-3-carbonitrile;

y) 3-{1-[3-(3-cyano-1H-indol-5-yl)propyl]piperidin-4-yl}-1H-indole-5-carbonitrile;

z) 5-{3-[4-(6-fluoro-1H-indol-3-yl)piperidin-1-yl]propyl}-1H-indole-3-carbonitrile;

aa) 5-{3-[4-(4-fluoro-1H-indol-3-yl)piperidin-1-yl]propyl}-1H-indole-3-carbonitrile;

bb) 5-[3-(4-benzo[d]isothiazol-3-ylpiperazin-1-yl)propyl]-1H-indole-3-carbonitrile;

cc) 4-{1-[3-(3-cyano-1H-indol-6-yl)propyl]piperidin-4-yloxy}benzamide;

dd) 6-{3-[4-(2-cyano-3-methoxyphenyl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

ee) 6-{3-[4-(4-cyano-3-methoxyphenyl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

ff) 6-{3-[4-(4-cyano-2-methoxyphenyl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

gg) 4-[3-(4-pyrazol-1-ylmethyl-1-piperidyl)propyl]-1H-indole-3-carbonitrile;

hh) N-(6-{4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)acetamide;

ii) 5-{3-[(pyridin-3-ylmethyl)amino]propyl}-1H-indole-3-carbonitrile;

jj) 5-{3-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

kk) 5-[3-(4-pyrimidin-2-ylpiperazin-1-yl)propyl]-1H-indole-3-carbonitrile;

ll) 5-{3-[(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)amino]propyl}-1H-indole-3-carbonitrile;

mm) 5-{3-[4-(3-methoxyphenyl)-3-methylpiperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

nn) 5-{3-[4-(1-methyl-1H-imidazo[4,5-c]pyridin-4-yl)piperazin-1-yl]-propyl}-1H-indole-3-carbonitrile;

oo) N-(4-{1-[3-(3-cyano-1H-indol-5-yl)propyl]piperidin-4-ylmethyl}-phenyl)acetamide;

pp) 5-{3-[4-(4-pyridin-3-ylthiazol-2-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

qq) ethyl 2-{4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl}-thiazole-

4-carboxylate;

rr) 5-{3-[3-(2-oxopyrrolidin-1-yl)propylamino]propyl}-1H-indole-3-carbonitrile;

ss) ethyl (6-{4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)carbamate;

tt) 5-{3-[4-(3-amino-2-oxo-2H-chromen-6-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

uu) methyl (6-{4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)carbamate;

vv) 2-{4-[3-(3-cyano-1H-indol-5-yl)propyl]-piperazin-1-yl}thiazole-4-carboxamide; or

ww) 4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazine-1- thiocarboxamide;

or a pharmaceutically acceptable salt, solvate, stereoisomer or mixture thereof.

Claim 5. (Currently Amended) A process for the preparation of a compound of formula I according to Claim 1 or a salt thereof comprising reacting

a) a compound of the formula II



II

~~in which~~ wherein

L^1 is Cl, Br, I, OH, a reactively esterified OH group or a diazonium group, and R^1, D, E, R^{12}, p and X^1 are as defined in Claim 1,

b) with a compound of the formula III



III

~~in which~~ wherein

L^2 is H or a metal ion, and E, G, X^2 and Z are as defined in Claim 1,

and optionally

c) converting the resultant compound of the formula I into a salt by treatment with an acid.

Claim 6. (Previously Presented) A process for the preparation of a pharmaceutical composition, comprising converting a compound of Claim 1 into a suitable dosage form together with at least one solid, liquid or semi-liquid excipient or adjuvant.

Claim 7. (Previously Presented) A pharmaceutical composition comprising at least one compound of Claim 1 and a pharmaceutically acceptable carrier.

Claim 8. (Cancelled)

Claim 9. (Currently Amended) A method for ~~modulating~~ inhibiting the activity of an excitatory amino acid in a cell, comprising contacting said cell with a compound of claim 1.

Claim 10. (Currently Amended) A method for ~~modulating~~ inhibiting the activity of a glycine transporter comprising contacting said transporter with a compound of claim 1.

Claim 11. (Cancelled)

Claim 12. (Currently Amended) A method for ~~preventing or~~ treating a 5HT-

mediated disease comprising administering to a host in need thereof a compound of claim 1.

Claim 13. (Currently Amended) A method according to Claim 12, wherein said disease is ~~selected from the group comprising~~ depression, strokes, cerebral ischaemia, extrapyramidal motor side effects of neuroleptics and of Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, brain and spinal cord trauma, obsessive-compulsive disorder, sleeping disorders, tardive dyskinesia, learning disorders, age-related memory disorders, eating disorders, and/or sexual dysfunctions.

Claim 14. (Currently Amended) A method for treating ~~and/or preventing~~ schizophrenia, depression, dementia, Parkinson's disease, Alzheimer's disease, Lewy bodies dementia, Huntington's disease, Tourette's syndrome, anxiety, learning and memory impairments, neurodegenerative diseases, cognitive impairments, nicotine dependence or pain comprising administering to a host in need thereof a compound of claim 1.

Claim 15. (Previously Presented) A method for combating neurodegenerative diseases, cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cerebral ischaemia, infarction or psychoses comprising administering to a host in need thereof a compound of claim 1.

Claim 16. (Previously Presented) A method for combating neurodegenerative diseases, cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cerebral ischaemia, infarction or psychoses comprising administering to a host in need thereof a pharmaceutical composition of claim 7.

Claim 17. (Cancelled)

Claim 18. (Withdrawn, Currently Amended) A compound of the formula II



II

~~in which~~ wherein

L^1 is Cl, Br, I, OH, a reactively esterified OH group or a diazonium group, and R^1, D, E, R^{12}, p and X^1 are as defined in Claim 1.

Claim 19. (Withdrawn, Currently Amended) A compound of the formula III



III

~~in which~~ wherein

L^2 is H or a metal ion, and E, G, X^2 and Z are as defined in Claim 1.

Claim 20. (Withdrawn, Currently Amended) A compound of the formula Ia



Ia

wherein

R^1 is H, A or SO_2A

A is straight-chain or branched alkyl having from 1 to 10 carbon atoms, alkenyl having from 2 to 10 carbon atoms or alkoxyalkyl having from 2 to 10 carbon atoms, and

D-E $R^2C=CR^4$, wherein R^2 is H or methyl and R^4 is CN

X^1 is $(CHR^7)_g$

g is 1, 2, 3, 4, 5 or 6,

R^7 is selected, independently, from the meanings indicated for R^2 to R^5;

Y is CH or N,

q is 0,

p and r are, independently of one another, 0, 1, 2 or 3

Hal is F, Cl, Br or I,

R^{12} and R^{13}, independently of one another, are selected from the meanings of R^4 other than H and are, independently of one another, Hal, CN, NO_2, OR^6, $N(R^6)_2$, NO_2, CN, $COOR^6$, $CON(R^6)_2$, NR^6COR^6, $NR^6CON(R^6)_2$, NR^6SO_2A, COR^6, SO_2NR^6, $S(O)_wA$, $OOCR^6$ and/or C(NH)NOH, and

X^2-Z is selected from the group consisting of





~~in which~~ wherein

X^2 is a bond,

R^{14} is selected, independently, from Hal, A, $(CH_2)_nHet$, $(CH_2)_nAr$, $(CH_2)_nCOO(CH_2)_mAr$, $(CH_2)_nCOO(CH_2)_mHet$, $(CH_2)_nOR^6$, $(CH_2)_nO(CH_2)_mAr$, $(CH_2)_nO(CH_2)_mHet$, $(CH_2)_nN(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)(CH_2)_mHet$, $(CH_2)_nSO_2N(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)SO_2(CH_2)_mAr$, $(CH_2)_nSO_2N(R^6)(CH_2)_mHet$, $(CH_2)_nN(R^6)SO_2(CH_2)_mHet$, $(CH_2)_nN(R^6)_2$, $(CH_2)_nNHOA$, $(CH_2)_n(R^6)Het$, $(CH_2)_nOCOR^6$, $(CH_2)_nOC(O)N(R^6)_2$, $(CH_2)_nOC(O)NR^6(CH_2)_mAr$, $(CH_2)_nOC(O)NR^6(CH_2)_mHet$, $(CH_2)_nNR^6COOR^6$, $(CH_2)_nNR^6COO(CH_2)_mAr$, $(CH_2)_nNR^6COO(CH_2)_mHet$, or CN

w is 0, 1, 2 or 3,

t is 0, 1, 2, 3, 4 or 5, and

m is 0, 1, 2, 3, 4, or 5

n is 0, 1, 2, or 3

R' is H, A, $(CH_2)_nHet$, $(CH_2)_nAr$, cycloalkyl having from 3 to 7 carbon atoms or SO_2A;

or a pharmaceutically salt, solvate, stereoisomer, or mixture thereof.

Claim 21. (Previously Presented) A compound of the formula IIa



IIa

wherein R^1 and R^2 are as defined in claim 20; and

Y-Z is a radical of the formulae



or a radical of the formulae



or a pharmaceutically salt, solvate, stereoisomer, or mixture thereof.

Claim 22. (Withdrawn, Currently Amended) A compound of the formula Ia according to claim 20



Ia

wherein

R^1 is H or A

A is straight-chain or branched alkyl having from 1 to 10 carbon atoms, alkenyl having from 2 to 10 carbon atoms or alkoxyalkyl having from 2 to 10 carbon atoms, and

D-E $R^2C=CR^4$, wherein R^2 is H or methyl and R^4 is CN

X^1 is $(CHR^7)_g$

g is 3,

R^7 is selected, independently, from the meanings indicated for R^2 to R^5;

Y is CH or N,

q is 0,

p and r are, independently of one another, 0, 1, 2 or 3

Hal is F, Cl, Br or I,

R^{12} and R^{13}, are, independently of one another, Hal, CN, NO_2, OR^6, $N(R^6)_2$, NO_2, CN, $COOR^6$, $CON(R^6)_2$, NR^6COR^6, $NR^6CON(R^6)_2$, NR^6SO_2A, COR^6, SO_2NR^6, $S(O)_wA$, $OOCR^6$ and/or C(NH)NOH, and

X^2-Z is selected from the group consisting of





~~in which~~ wherein

X^2 is a bond,

R^{14} is selected, independently, from Hal, NO_2, OR^6, $N(R^6)_2$, CN, $COOR^6$, $CON(R^6)_2$, NR^6COR^6, $NR^6CON(R^6)_2$, NR^6SO_2A, COR^6, SO_2NR^6, $S(O)_wA$, $OOCR^6$ and/or C(NH)NOH,

w is 0, 1, 2 or 3,

t is 1, 2, 3, and

R' is H, A, $(CH_2)_nHet$, $(CH_2)_nAr$, cycloalkyl having from 3 to 7 carbon atoms or SO_2A;

or a pharmaceutically salt, solvate, stereoisomer, or mixture thereof.